Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate

BMC Biotechnology

Rong-Hong Hua¹  Ye-Nan Li¹  Zhen-Shi Chen¹  Li-Ke Liu¹  Hong Huo¹  Xiao-Lei Wang¹  Li-Ping Guo¹  Nan Shen¹  Jing-Fei Wang¹  Zhi-Gao Bu¹ 

[1] State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Maduan Street, Harbin 150001, PR China

关键词: Subunit vaccine;    Virus-like particle;    Mammalian cell line;    Japanese encephalitis virus;   

Others  :  834816
DOI  :  10.1186/1472-6750-14-62

 received in 2014-06-20, accepted in 2014-07-04,  发布年份 2014

【 摘 要 】

Background

Japanese encephalitis virus (JEV) is the most important cause of epidemic encephalitis in most Asian regions. There is no specific treatment available for Japanese encephalitis, and vaccination is the only effective way to prevent JEV infection in humans and domestic animals. The purpose of this study is to establish a new mammalian cell line stably and efficiently expressing virus-like particle of JEV for potential use of JEV subunit vaccine.

Results

We generated a new cell clone (BJ-ME cells) that stably produces a secreted form of Japanese encephalitis virus (JEV) virus-like particle (VLP). The BJ-ME cells were engineered by transfecting BHK-21 cells with a code-optimized cDNA encoding JEV prM and E protein expression plasmid. Cell line BJ-ME can stably produces a secreted form of Japanese encephalitis virus virus-like particle (JEV-VLP) which contains the JEV envelope glycoprotein (E) and membrane protein (M). The amount of JEV-VLP antigen released into the culture fluid of BJ-ME cells was as high as 15–20 μg/ml. JEV-VLP production was stable after multiple cell passages and 100% cell expression was maintained without detectable cell fusion or apoptosis. Cell culture fluid containing the JEV-VLP antigen could be harvested five to seven times continuously at intervals of 4–6 days while maintaining the culture. Mice immunized with the JEV-VLP antigen with or without adjuvant developed high titers of neutralizing antibodies and 100% protection against lethal JEV challenge.

Conclusion

These results suggest that the recombinant JEV-VLP antigen produced by the BJ-ME cell line is an effective, safe and affordable subunit Japanese encephalitis vaccine candidate, especially for domestic animals such as pig and horse.

【 授权许可】

   
2014 Hua et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Solomon T, Vaughn DW: Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol 2002, 267:171-194.
• [2]Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, Mackenzie JS, Poidinger M, McCall BJ, Mills PJ: An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust 1996, 165:256-260.
• [3]van den Hurk AF, Nisbet DJ, Johansen CA, Foley PN, Ritchie SA, Mackenzie JS: Japanese encephalitis on Badu Island, Australia: the first isolation of Japanese encephalitis virus from Culex gelidus in the Australasian region and the role of mosquito host-feeding patterns in virus transmission cycles. Trans R Soc Trop Med Hyg 2001, 95:595-600.
• [4]Mackenzie JS, Johansen CA, Ritchie SA, van den Hurk AF, Hall RA: Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr Top Microbiol Immunol 2002, 267:49-73.
• [5]Igarashi A, Tanaka M, Morita K, Takasu T, Ahmed A, Akram DS, Waqar MA: Detection of west Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol Immunol 1994, 38:827-830.
• [6]Halstead SB, Jacobson J: Japanese encephalitis. Adv Virus Res 2003, 61:103-138.
• [7]van den Hurk AF, Ritchie SA, Mackenzie JS: Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009, 54:17-35.
• [8]See E, Tan HC, Wang D, Ooi EE, Lee MA: Presence of hemagglutination inhibition and neutralization antibodies to Japanese encephalitis virus in wild pigs on an offshore island in Singapore. Acta Trop 2002, 81:233-236.
• [9]Pant GR: A serological survey of pigs, horses, and ducks in Nepal for evidence of infection with Japanese encephalitis virus. Ann N Y Acad Sci 2006, 1081:124-129.
• [10]Lim SI, Kweon CH, Tark DS, Kim SH, Yang DK: Sero-survey on Aino, Akabane, Chuzan, bovine ephemeral fever and Japanese encephalitis virus of cattle and swine in Korea. J Vet Sci 2007, 8:45-49.
• [11]Yang DK, Kweon CH, Kim BH, Hwang IJ, Kang MI, So BJ, Cho KO: The seroprevalence of Japanese encephalitis virus in goats raised in Korea. J Vet Sci 2007, 8:197-199.
• [12]Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K: Past, present, and future of Japanese encephalitis. Emerg Infect Dis 2009, 15:1-7.
• [13]McArthur MA, Holbrook MR: Japanese Encephalitis Vaccines. J Bioterror Biodef 2011, S1:2.
• [14]van-den-Hurk AF, Ritchie SA, Johansen CA, Mackenzie JS, Smith GA: Domestic pigs and Japanese encephalitis virus infection, Australia. Emerg Infect Dis 2008, 14:1736-1738.
• [15]Lindahl J, Boqvist S, Stahl K, Thu HT, Magnusson U: Reproductive performance in sows in relation to Japanese Encephalitis Virus seropositivity in an endemic area. Trop Anim Health Prod 2012, 44:239-245.
• [16]Xin YY, Ming ZG, Peng GY, Jian A, Min LH: Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 1988, 39:214-217.
• [17]Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang SC, Xiang CF, Bilker WB, Pan XP, Yao YJ, Xu ZW, Halstead SB: Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997, 176:1366-1369.
• [18]Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, Ohrr HC, Tang JL, Halstead SB: Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001, 358:791-795.
• [19]Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K: IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther 2009, 9:921-931.
• [20]Dubischar-Kastner K, Eder S, Buerger V, Gartner-Woelfl G, Kaltenboeck A, Schuller E, Tauber E, Klade C: Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010, 28:5197-5202.
• [21]Kikukawa A, Gomi Y, Akechi M, Onishi T, Manabe S, Namazue J, Fuke I, Ishikawa T, Okuno Y, Ueda S: Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated). Vaccine 2012, 30(13):2329-2335.
• [22]Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, Monath TP: Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 1999, 257:363-372.
• [23]Appaiahgari MB, Vrati S: Clinical development of IMOJEV (R)–a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther 2012, 12:1251-1263.
• [24]Halstead SB, Thomas SJ: New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 2011, 10:355-364.
• [25]Halstead SB, Thomas SJ: New vaccines for Japanese encephalitis. Curr Infect Dis Rep 2010, 12:174-180.26.
• [26]Heinz FX, Stiasny K: Flaviviruses and flavivirus vaccines. Vaccine 2012, 30:4301-4306.27.
• [27]Yasuda A, Kimura-Kuroda J, Ogimoto M, Miyamoto M, Sata T, Sato T, Takamura C, Kurata T, Kojima A, Yasui K: Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus. J Virol 1990, 64:2788-2795.
• [28]Konishi E, Pincus S, Paoletti E, Shope RE, Burrage T, Mason PW: Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 1992, 188:714-720.
• [29]Sato T, Takamura C, Yasuda A, Miyamoto M, Kamogawa K, Yasui K: High-level expression of the Japanese encephalitis virus E protein by recombinant vaccinia virus and enhancement of its extracellular release by the NS3 gene product. Virology 1993, 192:483-490.
• [30]Konishi E, Yamaoka M, Khin Sane W, Kurane I, Mason PW: Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol 1998, 72:4925-4930.
• [31]Kojima A, Yasuda A, Asanuma H, Ishikawa T, Takamizawa A, Yasui K, Kurata T: Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J Virol 2003, 77:8745-8755.32.
• [32]Hunt AR, Cropp CB, Chang GJ: A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J Virol Methods 2001, 97:133-149.
• [33]Konishi E, Fujii A, Mason PW: Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol 2001, 75:2204-2212.
• [34]Ikemura T: Codon usage and tRNA content in unicellular and multicellular organisms. Mol Biol Evol 1985, 2:13-34.
• [35]Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J: Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998, 72:1497-1503.
• [36]zur Megede J, Chen MC, Doe B, Schaefer M, Greer CE, Selby M, Otten GR, Barnett SW: Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000, 74:2628-2635.
• [37]Bolin SR, Ridpath JF, Black J, Macy M, Roblin R: Survey of cell lines in the American type culture collection for bovine viral diarrhea virus. J Virol Methods 1994, 48:211-221.
• [38]Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH: Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108:717-725.
• [39]Heinz FX, Allison SL: Structures and mechanisms in flavivirus fusion. Adv Virus Res 2000, 55:231-269.40.
• [40]Yamaji H, Segawa M, Nakamura M, Katsuda T, Kuwahara M, Konishi E: Production of Japanese encephalitis virus-like particles using the baculovirus-insect cell system. J Biosci Bioeng 2012, 114(6):657-662.
• [41]Yamaji H, Nakamura M, Kuwahara M, Takahashi Y, Katsuda T, Konishi E: Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells. Appl Microbiol Biotechnol 2013, 97(3):1071-1079.
• [42]Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G: Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
• [43]Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F: The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8(3):271-283.
• [44]Hua RH, Bu ZG: A monoclonal antibody against PrM/M protein of Japanese encephalitis virus. Hybridoma (Larchmt) 2011, 30:451-456.
• [45]Hua RH, Liu LK, Chen ZS, Li YN, Bu ZG: Comprehensive mapping antigenic epitopes of NS1 protein of Japanese encephalitis virus with monoclonal antibodies. PLoS One 2013, 8(6):e67553.
• [46]Hua RH, Liu LK, Huo H, Li YN, Guo LP, Wang XL, Qin CF, Bu ZG: Comprehensive mapping of a novel NS1 epitope conserved in flaviviruses within the Japanese encephalitis virus serocomplex. Virus Res 2014, 185:103-109.